Colombes, 17/2/20, match France contre Pays de Galles [rugby, phase de jeu de la rencontre gagnée par Galles 6 à 5] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58046

Colombes, 17/2/20, France contre Pays de Galles [phase de jeu du match de rugby remporté par Galles 6 à 5] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58050

Colombes, 17/2/20, France contre Pays de Galles [phase de jeu du match de rugby remporté par Galles 6 à 5] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58054

Colombes, 17/2/20, match France contre Pays de Galles [rugby, phase de jeu de la rencontre gagnée par Galles 6 à 5] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58055

Colombes, 17/2/20, match France contre Pays de Galles [rugby, phase de jeu de la rencontre gagnée par Galles 6 à 5] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58056

Colombes, 17/2/20, match France contre Pays de Galles [rugby, phase de jeu de la rencontre gagnée par Galles 6 à 5] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58059

Colombes, 17/2/20, match France contre Pays de Galles [rugby, phase de jeu de la rencontre gagnée par Galles 6 à 5] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58060

Colombes, 17/2/20, match France contre Pays de Galles [rugby, phase de jeu de la rencontre gagnée par Galles 6 à 5] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58061

Colombes, 17/2/20, match France contre Pays de Galles [rugby, phase de jeu de la rencontre gagnée par Galles 6 à 5] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58062

Colombes, 17/2/20, match France contre Pays de Galles [rugby, phase de jeu de la rencontre gagnée par Galles 6 à 5] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58063

Colombes, 17/2/20, match France contre Pays de Galles [rugby, phase de jeu de la rencontre gagnée par Galles 6 à 5] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58065

Endogeneous matching in university-industry collaboration: Theory and empirical evidence from the UK

We develop a two-sided matching model to analyze collaboration between heterogeneousacademics and firms. We predict a positive assortative matching in terms of both scientificability and affinity for type of research, but negative assortative in terms of ability on one sideand affinity in the other. In addition, the most able and most applied academics and the mostable and most basic firms shall collaborate rather than stay independent. Our predictionsreceive strong support from the analysis of the teams of academics and firms that proposeresearch projects to the UK's Engineering and Physical Sciences Research Council.

Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.

We assessed the safety, tolerability, and immunogenicity of a mixture of three synthetic peptides derived from the Plasmodium vivax circumsporozoite protein formulated in Montanide ISA 720 or Montanide ISA 51. Forty healthy malaria-naive volunteers were allocated to five experimental groups (A-E): four groups (A-D) were immunized intramuscularly with 50 and 100 μg/dose injections of a mixture of N, R, and C peptides formulated in the two different adjuvants at 0, 2, and 4 months and one group was administered placebo. Vaccines were immunogenic, safe, well tolerated, and no serious adverse events related to the vaccine occurred. Seroconversion occurred in > 90% of the vaccines and antibodies recognized the sporozoite protein on immunofluorescent antibody test. Vaccines in Montanide ISA 51 showed a higher sporozoite protein recognition and interferon production. Results encourage further testing of the vaccine protective efficacy.

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.

BACKGROUND: We aimed to compare panitumumab, a fully human monoclonal antibody against EGFR, plus radiotherapy with chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck. METHODS: In this international, open-label, randomised, controlled, phase 2 trial, we recruited patients with locally advanced squamous-cell carcinoma of the head and neck from 22 sites in eight countries worldwide. Patients aged 18 years and older with stage III, IVa, or IVb, previously untreated, measurable (≥10 mm for at least one dimension), locally advanced squamous-cell carcinoma of the head and neck (non-nasopharygeal) and an Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned (2:3) by an independent vendor to open-label chemoradiotherapy (two cycles of cisplatin 100 mg/m(2) during radiotherapy) or to radiotherapy plus panitumumab (three cycles of panitumumab 9 mg/kg every 3 weeks administered with radiotherapy) using a stratified randomisation with a block size of five. All patients received 70-72 Gy to gross tumour and 54 Gy to areas of subclinical disease with accelerated fractionation radiotherapy. The primary endpoint was local-regional control at 2 years, analysed in all randomly assigned patients who received at least one dose of their assigned protocol-specific treatment (chemotherapy, radiation, or panitumumab). The trial is closed and this is the final analysis. This study is registered with ClinicalTrials.gov, number NCT00547157. FINDINGS: Between Nov 30, 2007, and Nov 16, 2009, 152 patients were enrolled, and 151 received treatment (61 in the chemoradiotherapy group and 90 in the radiotherapy plus panitumumab group). Local-regional control at 2 years was 61% (95% CI 47-72) in the chemoradiotherapy group and 51% (40-62) in the radiotherapy plus panitumumab group. The most frequent grade 3-4 adverse events were mucosal inflammation (25 [40%] of 62 patients in the chemoradiotherapy group vs 37 [42%] of 89 patients in the radiotherapy plus panitumumab group), dysphagia (20 [32%] vs 36 [40%]), and radiation skin injury (seven [11%] vs 21 [24%]). Serious adverse events were reported in 25 (40%) of 62 patients in the chemoradiotherapy group and in 30 (34%) of 89 patients in the radiotherapy plus panitumumab group. INTERPRETATION: Panitumumab cannot replace cisplatin in the combined treatment with radiotherapy for unresected stage III-IVb squamous-cell carcinoma of the head and neck, and the role of EGFR inhibition in locally advanced squamous-cell carcinoma of the head and neck needs to be reassessed. FUNDING: Amgen.